Switching to a Second TNF-α Inhibitor in a Patient with Severe Juvenile Polyarthritis: A Clinical Case

Switching to a Second TNF-α Inhibitor in a Patient with Severe Juvenile Polyarthritis: A Clinical Case

Background. Insufficient efficacy or intolerance of the first TNF-α inhibitor in patients with juvenile idiopathic arthritis (JIA) is an indication for the appointment of a second inhibitor. Golimumab is a new TNF-α inhibitor registered for treating JIA under pediatric indications. Clinical Case Des...

Full description

Bibliographic Details
Main Authors: Ekaterina V. Denisova, Ekaterina I. Alexeeva, Tatyana M. Dvoryakovskaya, Margarita A. Soloshenko, Anna V. Mamutova, Kseniya B. Isayeva, Anna N. Fetisova
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2018-10-01
Series:Voprosy Sovremennoj Pediatrii
Subjects:
children
juvenile idiopathic arthritis
genetically engineered biological preparations
golimumab
infliximab
Online Access:https://vsp.spr-journal.ru/jour/article/view/1931

Internet

https://vsp.spr-journal.ru/jour/article/view/1931

Similar Items